Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 1575 of 2873 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/30/12
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 10/31/11
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 07/17/17
End: 12/16/24
Due: 12/16/25
Phase: N/A
Priority: Normal
Start: 08/31/05
End: 08/31/23
Due: 08/31/24
Phase: N/A
Priority: Normal
Start: 03/20/17
End: 05/20/21
Due: 05/20/22
Phase: N/A
Priority: Normal
Start: 09/01/20
End: 12/31/21
Due: 12/31/22
Phase: N/A
Priority: Normal
Start: 03/05/91
End: 06/05/02
Due: 06/05/03
Phase: N/A
Priority: Normal
Start: 09/12/19
End: 02/08/24
Due: 02/08/25
Phase: N/A
Priority: Normal
Start: 10/10/19
End: 10/26/20
Due: 10/26/21
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
Phase: N/A
Priority: Normal
Start: 06/10/08
End: 11/26/19
Due: 11/26/20
Phase: N/A
Priority: Normal
Start: 09/23/13
End: 09/17/19
Due: 09/17/20
Phase: N/A
Priority: Normal
Start: 08/21/19
End: 07/09/24
Due: 07/09/25
Phase: N/A
Priority: Normal
Start: 12/31/07
End: 09/30/09
Due: 09/30/10
Phase: N/A
Priority: Normal
Start: 03/07/25
End: 12/31/30
Due: 12/31/31
Phase: N/A
Priority: Normal
Start: 08/12/20
End: 01/31/26
Due: 01/31/27
Phase: N/A
Priority: Normal
Start: 04/14/23
End: 10/31/27
Due: 10/31/28
Phase: N/A
Priority: Normal
Start: 04/11/19
End: 07/30/25
Due: 07/30/26
Phase: N/A
Priority: Normal
Start: 06/30/05
End: 11/30/14
Due: 11/30/15
Phase: N/A
Priority: Normal
Start: 04/30/11
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 02/01/99
End: 01/16/02
Due: 01/16/03
Phase: N/A
Priority: Normal
Start: 12/31/03
End: 12/31/04
Due: 12/31/05
Phase: N/A
Priority: Normal
Start: 11/29/25
End: 03/01/31
Due: 03/01/32
Phase: N/A
Priority: Normal
Start: 06/27/24
End: 09/01/27
Due: 09/01/28
Phase: N/A
Priority: Normal
Start: 06/05/17
End: 10/01/19
Due: 10/01/20
Phase: N/A
Priority: Normal
Start: 02/28/94
End: 04/30/02
Due: 04/30/03